Warner Chilcott (WCRX) down soon after FDA approval
Warner Chilcott Plc (NASDAQ: WCRX) shares fell 1.6% to begin Thursday at $14.35. The company announced this week that the United States Food and Drug Administration has approved its new 400 mg mesalamine product indicated for the treatment of ulcerative colitis. The Company anticipates that it will commercially launch DELZICOL in March 2013. Share volume was 1.2 million, compared to an all-day average of 4.9 million
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here